Sep. 28, 2011
Contact: Liz Dowling, (415) 3888-2794
Dowling & Dennis Public Relations
E-mail:Liz@DowlingDennis.net
CHICAGO –Novian Health, developer of Novilase® Breast Therapy, announced that the company has received a Notice of Allowance for a new patent. The U.S. patent,Application No. 11/957,040, covers probe holders for interstitial energy treatment. The technology enables precise positioning of the laser and temperature monitoring probes during image-guided interstitial laser therapy.
.
The newly allowed patent comes on the heels of Novian Health’s announcement this summer that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) for the company to conduct a multi-center study of its Novilase Interstitial Laser Therapy (ILT) System. The company is currently qualifying sites and investigators for that study.
Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors. The company has previously received FDA 510(k) clearance for the treatment of breast fibroadenomas and currently offers Novilase at breast centers around the country that are participating in its ABLATE registry.
“The new patent covers technology that adds to the precision of Novilase therapy and eliminates technique variation, ” said Henry “Chip” Appelbaum, President and CEO of Novian Health. “This achievement further validates Novilase technology — and buttresses our already strong portfolio of intellectual property covering the monitoring and controlling of tumor ablation.”
About Novilase
Novilase is a laser-based device for destroying tumors. This minimally invasive alternative to conventional surgery provides a safe tumor treatment alternative while preserving the patient’s options for additional procedures or adjunctive therapies. This image-guided outpatient procedure does not require general anesthetic or a hospital stay. Multiple tumors can be treated during a single visit. Therapy outcomes may be assessed using a variety of currently available imaging technologies and other methods. Therapy consists of physician placement of two small gauge needles into the tumor site after localanesthetic, followed by initiation of the computer-controlled Novilase system. Treatment times vary from 15-30 minutes
About Novian Health
Novian Health Inc., located in Chicago, is a privately held medical device company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). Developed as an alternative to surgery, the company’s technology uses parametrically controlled heating for the ablation of tumors.Image-guided treatment of breast tumors is the first application of the technology, and Novilase also has the potential to treat tumors elsewhere in the body.
For more information, call (312) 266-7200 or access www.novianhealth.com and www.novilase.com
